Founded in 2007 as a spin out from Carnegie Mellon University, Carmell has created a unique and highly innovative patented technology based on biologically-active materials manufactured from allogenic human blood plasma. These Plasma-based Bioactive Materials (PBMs) contain highly concentrated natural regenerative factors that promote healing and reduce infections in multiple clinical settings. As a result, they help lower healthcare costs. Unlike previous approaches to delivering growth factors locally to injuries, Carmell has patented a process which fine-tunes the release of active biologics over different periods of time (weeks, days, months) when the body needs them most to accelerate healing.
Utilizing its proprietary crosslinking process, the company has successfully developed multiple PBM formulations such as pastes, putties, scaffolds, plugs and screws, using pooled plasma from healthy donors.